In the August 2007 issue of the Archives, Legat et al1 described the accelerated and improved clearance of psoriasis when alefacept is combined with narrowband (NB) UV-B phototherapy. Because all patients in this study were treated with alefacept and with a randomly selected body half exposed to NB UV-B phototherapy, the question remained as to whether the improvement seen was greater than what can be achieved with NB UV-B monotherapy. We present data from 16 patients with chronic plaque psoriasis requiring systemic or phototherapy who were enrolled in an institutional review board approved, randomized, double-blind, placebo-controlled study comparing alefacept with NB UV-B vs NB UV-B alone for the treatment of psoriasis.